Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Delphia Therapeutics | 2024 | Series A | $67.0M | Cambridge |
| 5Metis | 2024 | Series A | $5.5M | Durham |
| Umaro Foods | 2024 | Grant | $2.0M | Albany |
| Blacksmith Medicines | 2024 | Grant | $3.3M | San Diego |
| Remix Therapeutics | 2024 | Series Unknown | $60.0M | Cambridge |
| CIBO | 2024 | Series C | Undisclosed | Saint Louis Park |
| Deka Biosciences | 2023 | Series Unknown | $29.9M | Germantown |
| Georgiamune | 2023 | Series A | $75.0M | Gaithersburg |
| Evelo Biosciences | 2023 | Post Ipo Equity | $25.5M | Cambridge |
| TwinStrand Biosciences | 2023 | Series Unknown | $10.3M | Seattle |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 101 | Delphia Therapeutics | Series A | $67.0M | Cambridge, United States |
| 102 | 5Metis | Series A | $5.5M | Durham, United States |
| 103 | Umaro Foods | Grant | $2.0M | Albany, United States |
| 104 | Blacksmith Medicines | Grant | $3.3M | San Diego, United States |
| 105 | Remix Therapeutics | Series Unknown | $60.0M | Cambridge, United States |
| 106 | CIBO | Series C | Undisclosed | Saint Louis Park, United States |
| 107 | Deka Biosciences | Series Unknown | $29.9M | Germantown, United States |
| 108 | Georgiamune | Series A | $75.0M | Gaithersburg, United States |
| 109 | Evelo Biosciences | Post Ipo Equity | $25.5M | Cambridge, United States |
| 110 | TwinStrand Biosciences | Series Unknown | $10.3M | Seattle, United States |
Delphia Therapeutics operates and manages a laboratory that develops treatments for cancer cells.
5Metis is a new pure-play discovery company for crop health.
Umaro Foods uses green chemistry to unlock value-added ingredients and chemicals from seaweed
Blacksmith Medicines developing medicines targeting metal-dependent enzymes found in human physiology.
Remix Therapeutics is a biotechnology company that is working on developing small molecule medicines.
CIBO scales regenerative advanced platform technology that connects growers to incentives and enterprises to growers.
Early stage biotechnology company
Georgiamune is a biotechnology company developing next-generation immunotherapeutics for cancer and autoimmune diseases.
Evelo Biosciences is a biotechnology company that develops oral biologics for small intestinal axis with systemic therapeutic effects.
TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.
AltPep provides a novel approach for tackling amyloid diseases, with diagnostic, therapeutic and anti-biofilm applications.
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.
Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria.
Bitterroot Bio leverages the power of immunotherapy to develop and deliver novel medicines for cardiovascular disease.
Mozart is a biotech startup focusing on the development of disease-modifying therapies for autoimmune and inflammatory diseases.
CREATE Medicines is a clinical stage mRNA-immunotherapy company developing novel therapies for cancer and autoimmune diseases.
Function Oncology is a precision medicine company advancing a CRISPR-powered personalized functional genomics platform.
Vesigen Therapeutics is a biotechnology company that develops groundbreaking therapeutic products.
QurAlis is a biotechnology company that creates precision medicine solutions to cure ALS and FTD.
Ring Therapeutics is a gene therapy company focused on discovering and developing programmable genetic medicines.
Paratus Sciences is dedicated to advancing human health and health security by comprehending the biology of bats.
IgGenix is a biotechnology company.
Melonfrost is a biotechnology company based in Brooklyn, New York.
Developer of a pharmaceutical platform and drugs created for the treatment of the central nervous system.
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Alexandria Venture Investments has invested in 157 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Alexandria Venture Investments's top investment sectors include Biotechnology, Therapeutics, Health Care, Medical, Genetics. The firm invests across 25 different industry categories.
Among tracked funding rounds, Bitterroot Bio received $145.0M in a Series A round. Alexandria Venture Investments's total known invested capital is $3.8B.
Alexandria Venture Investments's average investment size is $37.7M across its portfolio of 157 companies.
Recent Alexandria Venture Investments portfolio additions include Delphia Therapeutics, 5Metis, Umaro Foods, Blacksmith Medicines, Remix Therapeutics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors